GSK plc (NYSE:GSK) Holdings Lifted by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC increased its holdings in shares of GSK plc (NYSE:GSK) by 8.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,969 shares of the pharmaceutical company’s stock after buying an additional 5,583 shares during the quarter. Koss Olinger Consulting LLC’s holdings in GSK were worth $2,299,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of GSK. Primecap Management Co. CA grew its holdings in shares of GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after buying an additional 10,407,905 shares in the last quarter. FMR LLC grew its stake in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Mondrian Investment Partners LTD grew its stake in GSK by 17.6% in the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after purchasing an additional 874,004 shares in the last quarter. Fisher Asset Management LLC grew its stake in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its stake in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE:GSK opened at $40.35 on Wednesday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The business has a 50-day moving average of $36.30 and a two-hundred day moving average of $36.96. The stock has a market capitalization of $83.51 billion, a P/E ratio of 25.37, a P/E/G ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 3.90%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.